Skip to main navigation Skip to search Skip to main content

(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology

  • Aubin Moutal
  • , Lindsey A. Chew
  • , Xiaofang Yang
  • , Yue Wang
  • , Seul Ki Yeon
  • , Edwin Telemi
  • , Seeneen Meroueh
  • , Ki Duk Park
  • , Raghuraman Shrinivasan
  • , Kerry B. Gilbraith
  • , Chaoling Qu
  • , Jennifer Y. Xie
  • , Amol Patwardhan
  • , Todd W. Vanderah
  • , May Khanna
  • , Frank Porreca
  • , Rajesh Khanna

Research output: Contribution to journalArticlepeer-review

Abstract

Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2.2-CRMP2 interaction identified (S)-lacosamide [(S)-LCM], the inactive enantiomer of the Food and Drug Administration-approved antiepileptic drug (R)-lacosamide [(R)-LCM, Vimpat]. We show that (S)-LCM, but not (R)-LCM, inhibits CRMP2 phosphorylation by cyclin dependent kinase 5, a step necessary for driving CaV2.2 activity, in sensory neurons. (S)-lacosamide inhibited depolarization-induced Ca 2+ influx with a low micromolar IC 50. Voltage-clamp electrophysiology experiments demonstrated a commensurate reduction in Ca 2+ currents in sensory neurons after an acute application of (S)-LCM. Using constellation pharmacology, a recently described high content phenotypic screening platform for functional fingerprinting of neurons that uses subtype-selective pharmacological agents to elucidate cell-specific combinations (constellations) of key signaling proteins that define specific cell types, we investigated if (S)-LCM preferentially acts on certain types of neurons. (S)-lacosamide decreased the dorsal root ganglion neurons responding to mustard oil, and increased the number of cells responding to menthol. Finally, (S)-LCM reversed thermal hypersensitivity and mechanical allodynia in a model of postoperative pain, and 2 models of neuropathic pain. Thus, using (S)-LCM to inhibit CRMP2 phosphorylation is a novel and efficient strategy to treat pain, which works by targeting specific sensory neuron populations.

Original languageEnglish (US)
Pages (from-to)1448-1463
Number of pages16
JournalPain
Volume157
Issue number7
DOIs
StatePublished - Jul 1 2016

Keywords

  • (S)-lacosamide
  • CRMP2
  • CaV2.2
  • Calcium imaging
  • Constellation pharmacology
  • Neuropathic pain
  • Postoperative pain

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint

Dive into the research topics of '(S)-lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology'. Together they form a unique fingerprint.

Cite this